Glaucoma, Ocular Hypertension
Conditions
Keywords
Glaucoma, Ocular hypertension, OHT, Cataract, Timolol, Lens diseases
Brief summary
The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery. The study is conducted in two stages. The first stage (Stage 1/Phase 1) is intended to study the safety of 3 different doses of the study medication (called TimoD implant). The second stage (Stage 2/Phase 2) of the study is intended to study in greater detail the efficacy and safety of the 3 doses of the TimoD implant in comparison to a standard approved medication, timolol eye drops for 3 years.
Detailed description
Timolol will be administered using an investigational drug product called the TimoD implant. The implant will be placed in one eye (the study eye) using an instrument called an injector system (an investigational device). The implant procedure will be performed during cataract surgery. Stage 1: Three dose levels of the TimoD implant (low, intermediate, and high) will be evaluated in three groups of six participants each. Participants will be assigned sequentially to a treatment group and will receive a single implant containing one of the three dose levels. Participants in Stage 1 will be followed for 1 year. Stage 2: The same three dose levels of the TimoD implant will be evaluated further. In addition, a fourth treatment group receiving an approved control treatment (timolol eye drops) will be included. Six participants will be randomized to each treatment group. Participants in Stage 2 will be followed for 3 years.
Interventions
DRUGTimoD implant
Consists of 1 TimoD implant administration in the study eye.
DEVICEInjector system
This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.
Timolol eye drops will be self-admnistered twice daily in the study eye approximately 12 hours apart throughout the study
Sponsors
EyeD Pharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE
Intervention model description
Stage 1 (Phase 1) will use a sequential assignment design, whereas Stage 2 (Phase 2) will use a parallel assignment design.
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Capable of giving signed informed consent. * In good general and mental health without ongoing clinically significant abnormalities in medical history. * Open-angle glaucoma or ocular hypertension and age-related cataract eligible for intra-capsular IOL placement. * Successful, uncomplicated cataract surgery
Exclusion criteria
* Subjects with a history of hypersensitivity or contraindications to β- blockers. * Participants using any systemic or topical drug known to interfere with visual performance, pupil dilation, or iris structure * Significant risks caused by washout of ocular hypotensive medications. * Clinically significant ocular pathology other than OHT, glaucoma and cataract.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stage 1: Number (%) of participants experiencing adverse events | From Screening (up to Day -41) to end of stage 1 (Month 13) |
| Stage 1: Number (%) of participants experiencing adverse events of special interest (AESI) | From Screening (up to Day -41) to end of stage 1 (Month 13) |
| Stage 2: Proportion of responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM IOP) | Month 3 |
| Stage 2: Proportion of time-matched responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM and 10 AM) | Month 3 |
Countries
Panama
Contacts
CONTACTEyeD Pharma
Outcome results
None listed